Skip to content

Radiology Rewired | Conversations that move radiology forward
Catch up on season 1 before the new season drops

Tune in
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
Press Release

Penumbra Announces Partnership with RapidAI

The companies will work to develop clinical and communications modules for pulmonary embolism, a deadly condition involving blood clots in the lungs.

Share to

The companies will work to develop clinical and communications modules for pulmonary embolism, a deadly condition involving blood clots in the lungs.

Alameda, Calif. — November 10, 2020 —Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced a new partnership to develop solutions to enable faster clinical decision-making for pulmonary embolism (PE) diagnosis and procedures with RapidAI, a company that offers a clinically proven, data-driven artificial intelligence (AI) platform that empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients. “PE is at the precipice of a transformation in how patients affected by this condition are being treated. Several advances have been made during the last few years largely due to the PERT Consortium’s efforts, combined with innovation in therapeutic options,“ said Robert Lookstein, MD MHCDL FSIR FAHA FSVM, president of the PERT Consortium, professor of Radiology and Surgery at Icahn School of Medicine at Mount Sinai (ISMMS) and executive vice chairman in The Department of Diagnostic, Molecular, and Interventional Radiology for the Mount Sinai Health System. “This exciting new partnership will undoubtedly help bring more awareness to this very deadly disease. The entire field wants to rapidly bring more therapeutic options to a broader segment of the population. We collectively believe this will only improve outcomes.” Penumbra and RapidAI will work together to develop several clinical and communications modules for pulmonary embolism, which is a deadly condition involving blood clots in the lungs. The modules are aimed to streamline triage and decision-making by processing CT scans and delivering clear, easy-to-interpret CT images directly to the physician. In addition, this partnership comes at a very important time, as the medical community is dealing with the COVID-19 pandemic where patient triage and remote access have become critical to the healthcare system. “COVID-19 has heightened the need for AI technology that powers physicians’ ability to be connected to their healthcare institutions and care teams from remote locations and to speed up patient care,” said Don Listwin, chief executive officer, Rapid AI. “We are thrilled to be partnering with one of the most innovative medical device companies, Penumbra, to advance the field of PE by rising to these challenges with our powerful AI solutions.” This new partnership with RapidAI demonstrates Penumbra’s continued commitment to advancing solutions for pulmonary embolism and follows the recent launch of the Indigo® System with Lightning™ Intelligent Aspiration, Penumbra’s newest generation technology for the removal of blood clots in the arteries and veins and for the treatment of pulmonary embolism. “Penumbra has been at the forefront of technology to address unmet clinical needs - be it in stroke, virtual rehab, intelligent aspiration and now pulmonary embolism,” said Adam Elsesser, chairman and chief executive officer, Penumbra Inc. “This partnership with RapidAI is another example of Penumbra’s commitment to provide cutting-edge solutions that help address the challenges faced by the medical community. We look forward to taking on this next frontier in the field of PE.” About Penumbra Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra, the Penumbra P logo, Indigo, and Lightning are trademarks of Penumbra, Inc. For more information, visit www.penumbrainc.com. About RapidAI RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained over 1 million scans from more than 1,600 hospitals in over 50 countries, the Rapid® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview®, a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically proven, data-driven technology. With its validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit www.rapidai.com . Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the impact of the COVID-19 pandemic on our business, results of operation and financial condition; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; and potential adverse regulatory actions. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 26, 2020, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the SEC on May 7, 2020, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the SEC on August 3, 2020 and our Quarterly Report on Form 10-Q for the quarter September 30, 2020 filed with the SEC on November 2, 2020. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Contact PR

Jessica Stebing

Jessica Stebing

Group Manager, Marketing Communications

stebing@rapidai.com

Get to know Rapid in the real world

View All Resources
Video - Lumina Webinar Replay

Webinar

The end of manual head & neck reconstructions // A faster path with Lumina 3D

In this webinar, we focus on the challenges and opportunities in 3D head and neck CTA reconstruction workflows. Our speakers share real-world insights on how the Lumina 3D platform can have a tangible impact on CT workflow, scanner throughput, and diagnosis.
Radiology Rewired Podcast - Episode 1 Thumbnail

Podcast

AI Meets Imaging | Radiology Rewired | Ep. 1

In the debut episode of Radiology Rewired, RapidAI’s new clinician-led podcast hosted by Dr. Singh, Dr. Greg Albers—founder of RapidAI and professor of neurology at Stanford University—shares the story behind one of medicine’s most important breakthroughs: extending the stroke treatment window to 24 hours. Dr. Albers recounts how decades of imaging research led from early diffusion-perfusion MRI to automated AI tools that changed global stroke guidelines and transformed how teams diagnose and treat patients. This episode explores how deep clinical AI is reshaping radiology and why credible, clinician-led innovation remains essential for the next generation of healthcare technology.
Resources - multistakeholder white paper

White paper

The clinical AI champion's guide: getting to "yes" in complex health systems

This guide is designed for internal champions, clinicians, service line leaders, and administrators who believe in the potential of AI to improve care and operations. It offers practical insights from a C-suite advisory panel from leading health systems across the nation on how decisions are made, who typically drives them forward, and what tools and strategies are proving most effective in securing alignment and buy-in across the system.